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We appreciated the article by Gonnert and colleagues on hyperbilirubinemia from septic hepatocellular excretory dysfunction [1] , a still improperly characterized issue in clinical settings. We address postoperative liver resection patients with prominently conjugated (~50 to 70 % conjugated) hyperbilirubinemia. Less relevant causes include transient insufficiency of remnant liver and prolonged intraoperative ischemia [2] ; a threatening cause is occult sepsis.
The pattern may be similar: prominently conjugated hyperbilirubinemia, with normal/moderately altered aspartate aminotransferase and alanine aminotransferase, alkaline phosphatase and gamma-glutamyltransferase. In occult sepsis this involves the risk of dismissing hyperbilirubinemia as transient liver insufficiency expected to spontaneously recover, with dreadful consequences, also because sepsis and liver insufficiency might coexist [3] . In post-hepatectomy patients, interpretation of hyperbilirubinemia is challenged by unreliability of landmarks based on hepatobiliary enzymes. Aspartate aminotransferase and alanine aminotransferase increase due to par-enchymal transection/ischemia, and then decrease at different rates [4] ; alkaline phosphatase and gammaglutamyltransferase (enzymes of cholestasis) markedly decrease, and then slowly increase reflecting liver regeneration [2, 5] . We even observed isolated hyperbilirubinemia (>15.0 mg/dl, 50 % conjugated) with near-normal alkaline phosphatase and gamma-glutamyltransferase and good clinical condition in occult sepsis from posthepatectomy biliary stenosis and initial cholangitis. Although this was partly obstructive cholestasis (a less pertinent example), it better emphasizes the need to promptly exclude sepsis or other complications as causes of hyperbilirubinemia, without relying on common clinical/biochemical criteria.
The light shed by Gonnert and colleagues [1] on septic hepatocellular excretory dysfunction has major translational implications: as obvious as the issue may appear to updated investigators, greater awareness of this deceitful presentation of sepsis may still avoid dangerous delays in treatment. 
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We appreciate the comments from Chiarla and colleagues since they describe a typical but challenging dilemma of diagnosing sepsis-associated liver dysfunction [6] . It is important to note that liver dysfunction occurs frequently and early in sepsis, often without hepatocellular injury [7] . Sepsis induces a reprogramming of metabolic functions in parallel with a severity-dependent disruption of phase I and phase II biotransformation and canalicular transport [8] , whereby activation of PI3kinase-dependent signaling could be a pathogenetic mechanism [7] . Since these changes influence prognosis and significantly precede conventional markers [7, 9] , there is an urgent need for new diagnostic strategies.
Nowadays, the plasma disappearance rate of indocyanine green is the best evaluated test to assess hepatic function. This test reflects excretory dysfunction yet underestimates impaired canalicular transport [9] . A recent report suggested the LiMAx test, a new non-invasive diagnostic tool for determining liver function based on a breath test [10] . Both tests are superior to conventional laboratory markers in predicting patient morbidity and mortality. In addition to the presented biophotonic techniques in our study, another future perspective in early diagnosing liver dysfunction in the critically ill might be plasma bile acids. In septic patients, levels of both conjugated and unconjugated chenodeoxycholic and taurodeoxycholic acid were increased on the day of diagnosis, showing a stronger correlation with 28-day mortality than bilirubin levels [7] .
While there is still a need for improving our spectrum of diagnostic tools, another true challenge will be the development of specific therapeutic strategies for critically ill patients with liver dysfunction.
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